



# Otic Antibiotics

## Therapeutic Class Review (TCR)

August 1, 2014

---

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

Attention: Copyright Administrator  
Intellectual Property Department  
Provider Synergies, L.L.C.  
10101 Alliance Road, Suite 201  
Cincinnati, Ohio 45242

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [PSTCReEditor@magellanhealth.com](mailto:PSTCReEditor@magellanhealth.com).

## FDA-APPROVED INDICATIONS

Drug Name	Manufacturer	Indication(s)
ciprofloxacin 0.2% (Cetraxal <sup>®</sup> ) <sup>1</sup>	generic	<ul style="list-style-type: none"> <li>Acute otitis externa due to susceptible isolates of <i>Pseudomonas aeruginosa</i> or <i>Staphylococcus aureus</i> in pediatrics (age one year and older) and adults</li> </ul>
ciprofloxacin 0.3% and dexamethasone 0.1% suspension (Ciprodex <sup>®</sup> Otic) <sup>2</sup>	Alcon	<ul style="list-style-type: none"> <li>Acute otitis media in pediatric patients (age six months and older) with tympanostomy tubes</li> <li>Acute otitis externa in pediatric (age six months and older), adult, and elderly patients</li> </ul>
ciprofloxacin 0.2% and hydrocortisone 1% suspension (Cipro HC <sup>®</sup> Otic) <sup>3</sup>	Alcon	<ul style="list-style-type: none"> <li>Acute otitis externa in adult and pediatric patients, (one year and older)</li> </ul>
hydrocortisone 1%, neomycin sulfate 3.3 mg, colistin sulfate 3 mg, thonzonium bromide 0.05% suspension (Coly-mycin <sup>®</sup> S) <sup>4</sup>	JHP Pharmaceuticals	<ul style="list-style-type: none"> <li>Treatment of superficial bacterial infections of the external auditory canal in adult and pediatric patients*</li> <li>Treatment of infections of mastoidectomy and fenestration cavities in adult and pediatric patients*</li> </ul>
hydrocortisone 1%, neomycin sulfate 5 mg, polymyxin B 10,000 units solution and suspension (Cortisporin <sup>®</sup> ) <sup>5</sup>	generic	<ul style="list-style-type: none"> <li>Treatment of superficial bacterial infections of the external auditory canal in adults and pediatric patients ( 2 years and older)</li> <li>Treatment of infections of mastoidectomy and fenestration cavities (suspension only) in adults and pediatric patients (2 years and older)</li> </ul>
hydrocortisone 1%, neomycin sulfate 3.3 mg, colistin sulfate 3 mg, thonzonium Br 0.05% suspension (Cortisporin <sup>®</sup> -TC) <sup>6</sup>	JHP Pharmaceuticals	<ul style="list-style-type: none"> <li>Treatment of superficial bacterial infections of the external auditory canal in adult and pediatric patients*</li> <li>Treatment of infections of mastoidectomy and fenestration cavities in adult and pediatric patients*</li> </ul>
ofloxacin 0.3% solution (Floxin <sup>®</sup> Otic) <sup>7</sup>	generic	<ul style="list-style-type: none"> <li>Otitis externa in adults and pediatric patients (six months and older)</li> <li>Chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes</li> <li>Acute otitis media in pediatric patients (one year and older) with tympanostomy tubes</li> </ul>

\* Specific pediatric age not listed in package insert.

## OVERVIEW<sup>8, 9, 10, 11</sup>

The standard treatment for acute otitis media (AOM) has been the use of systemic antibiotics while topical (otic) therapy antibiotic is generally used for otitis externa. Topical antibiotics, such as ofloxacin (Floxin Otic) and ciprofloxacin with dexamethasone (Ciprodex), may help to decrease adverse reactions and reduce the potential for antibiotic resistance when used in patients with AOM and with tympanostomy tubes. The patent tympanostomy tube does not change the spectrum of causative agents in acute otitis media.

Otitis externa is an acute inflammation of the external auditory canal. Commonly referred to as “swimmer’s ear” or “tropical ear”, this condition is often precipitated by water exposure or trauma. Common pathogens implicated in otitis externa are *Pseudomonas aeruginosa* and *Staphylococcus aureus*, often occurring as a polymicrobial infection. Patients will typically complain of otalgia and

otorrhea, and the ear canal may appear erythematous and swollen. It is imperative that the ear canal be cleared of any discharge or debris that can occlude the canal since the presence of such material can keep the canal moist and interfere with topical treatment. All ages are affected, with a peak incidence in children aged seven to 12 years. In 2006, The American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) released guidelines for the management of acute otitis externa (AOE) in patients over two years of age.<sup>12</sup> Clinicians should use topical preparations for initial therapy of diffuse, uncomplicated AOE. Systemic antimicrobial therapy should not be used unless there is extension outside the ear canal or the presence of specific host factors that would indicate a need for systemic therapy. A topical aminoglycoside combined with a second antibiotic and a topical steroid, such as the combination of neomycin, polymyxin B, and hydrocortisone that is commonly prescribed to treat AOE. However, caution must be used to watch for a hypersensitivity reaction to the neomycin and ototoxicity from the aminoglycoside. This preparation should not be used in cases of a perforated tympanic membrane. However, if the tympanic membrane is known or suspected to be perforated, agents with ototoxic potential, such as aminoglycosides, should not be used. Fluoroquinolones are not associated with ototoxicity, and ofloxacin is safe in cases of a perforated tympanic membrane. If the patient fails to respond to the initial therapeutic option within 48 to 72 hours, the clinician should reassess the patient to confirm the diagnosis of diffuse AOE and to exclude other causes of illness.

Clinical Practice Guidelines for acute otitis media (AOM) were updated in 2013 by the American Academy of Pediatrics (AAP) with extensive literature review performed by AAP, the Agency for Healthcare Research and Quality (AHRQ) and the Southern California Evidence-Based Practice Center. The guidelines address the diagnosis, pain management, medication treatment options of infection and pain, and the preventative and recurrent management of AOM in children six months to 12 years of age. These guidelines are an update to the 2004 AOM guidelines from AAP and the American Academy of Family Physicians (AAFP).<sup>13</sup> The guidelines focus on systemic therapy. The guidelines define that an antibiotic should be prescribed in children at least six months of age who display severe signs or symptoms of bilateral or unilateral AOM occurring for at least 48 hours or temperature 39 degrees C or higher or for non-severe bilateral AOM in children six months to 23 months. The observational period prior to starting an antibiotic is now suggested along with a choice of not waiting and initiating antibiotic treatment. The guidelines emphasize on the accuracy of diagnosing AOM. When an antibiotic is needed, amoxicillin continues to be the first-line treatment unless the child has received it in the last 30 days, is allergic to penicillin, or has concurrent purulent conjunctivitis. Treatment options in these patients should include an antibiotic with additional  $\beta$ -lactamase coverage. Topical agents were only discussed in the guidelines as a treatment option when tympanostomy tubes for recurrent AOM are used.<sup>14</sup> However, specific recommendations for use of topical antibiotics were not included in these guidelines.

Chronic suppurative otitis media (CSOM) is defined as a perforated tympanic membrane with persistent drainage from the middle ear and initiated by an episode of acute infection. *P. aeruginosa* is the most common causative organism followed by *S. aureus*. The yearly incidence of CSOM is estimated to be 39 cases per 100,000 persons in children and adolescents aged 15 years and younger in the United States. CSOM responds more frequently to topical than to systemic therapy. Successful topical therapy includes administration of antibiotic drops and aural irrigation. The antibiotic should have activity against both gram-negative and gram-positive organisms. Aminoglycosides and fluoroquinolones both have spectrum of activity against gram-negative and gram-positive organisms.

However, aminoglycosides may potentially be ototoxic and therefore are not recommended to be used if the tympanic membrane is perforated.<sup>15</sup>

## PHARMACOLOGY

Ofloxacin and ciprofloxacin are fluoroquinolones and have activity against a wide range of gram-negative and gram-positive microorganisms. Fluoroquinolones act by inhibiting the DNA gyrase enzyme that is essential for DNA replication, repair, deactivation, and transcription.

Hydrocortisone and dexamethasone are corticosteroids that control inflammation, edema, pruritus, and other dermal reactions.

Colistin sulfate is an antibiotic with bactericidal action against most gram-negative organisms, notably *P. aeruginosa*, *Escherichia coli*, and *Klebsiella-Aerobacter* sp.

Neomycin sulfate is an aminoglycoside and broad-spectrum antibiotic that is bactericidal to many pathogens, notably *S. aureus* and *Proteus* sp. Neomycin irreversibly binds to the 30S subunit of bacterial ribosomes, blocking the recognition step in protein synthesis and causing misreading of the genetic code.

Polymyxin B increases the permeability of bacterial cell membranes and is bactericidal against almost all gram-negative bacilli except the *Proteus* group.

Thonzonium bromide is a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate.

It is thought that because topical application establishes and maintains drug concentrations at the site of infection that are well above the minimum inhibitory concentration, resistance is not likely to develop following topical use. A systematic review of the evidence regarding the development of antibiotic resistance with ototopical treatment indicated that antibiotic resistance is rare, although in none of the studies was resistance the main study question.<sup>16,17,18</sup>

## PHARMACOKINETICS

Due to the topical application of these products, minimal systemic absorption is expected.<sup>19</sup>

Ciprofloxacin (Cetraxal): After administration of 0.25 mL of Cetraxal, plasma concentrations were not measurable (total dose: 0.5 mg ciprofloxacin). The maximum plasma concentration is expected to be less than 5 ng/mL.<sup>20</sup>

Ofloxacin (Floxin Otic): The concentration of ofloxacin in middle ear fluid is variable based on the patient's disease state. Serum ofloxacin concentrations were low in patients with tympanostomy tubes and/or perforated tympanic membranes.<sup>21</sup>

Ciprofloxacin/dexamethasone (Ciprodex): Both ciprofloxacin and dexamethasone appear in the plasma at measurable concentrations although the concentrations are approximately 0.1 percent and 14 percent, respectively, of an oral dose of ciprofloxacin 250 mg tablet and dexamethasone 0.5 mg tablet.<sup>22</sup> Peak plasma concentrations for both components were seen between 15 minutes and 2 hours after dose application.

Ciprofloxacin/hydrocortisone (Cipro HC): Ciprofloxacin concentrations in the blood are expected to be below the level of detection and therefore have not been measured. Levels of hydrocortisone are not distinguishable from naturally occurring levels.<sup>23</sup>

## **CONTRAINDICATIONS/WARNINGS**<sup>24,25,26,27,28,29,30</sup>

Corticosteroid and neomycin containing products should not be used in viral infections involving the external ear canal, such as varicella and herpes simplex.

Neomycin may induce permanent sensorineural hearing loss due to cochlear damage. Neomycin-containing products should be used cautiously in any patient with a perforated tympanic membrane. It may also cause cutaneous sensitization.

Ciprodex Otic and Floxin Otic are both sterile products. Cipro HC Otic is a non-sterile product and should not be used if the tympanic membrane is perforated.

Cipro HC, Cetraxal, and Ciprodex Otic are contraindicated in patients with a history of hypersensitivity to ciprofloxacin, quinolones, or other components (e.g., dexamethasone or hydrocortisone) of these products. Ofloxacin Otic is contraindicated in patients with a history of hypersensitivity to ofloxacin, other quinolones, or any components of this product. Ciprofloxacin otic is contraindicated in patients with ciprofloxacin hypersensitivity.

None of the products included in this review are approved for ophthalmic use, inhalation, or for injection.

## **DRUG INTERACTIONS**<sup>31,32,33,34,35,36,37</sup>

Since all agents are applied topically and have negligible systemic absorption; no documented drug interactions are currently available.

## ADVERSE EFFECTS

### Patients with Otitis Externa

Drug	Pruritus	Application site reaction	Dizziness	Ear pain/discomfort	Vertigo	Headache	Ototoxicity
ciprofloxacin (Cetraxal) <sup>38</sup>	2-3	nr	nr	2-3	nr	2-3	nr
ciprofloxacin/dexamethasone (Ciprodex Otic) <sup>39</sup> n=537	1.5	nr	nr	0.4	nr	nr	nr
ciprofloxacin/hydrocortisone (Cipro HC Otic) <sup>40</sup> n=564	0.4	nr	nr	nr	nr	1.2	nr
ofloxacin (Floxin Otic) <sup>41</sup> n=229	1.2-4	3-16.8	1	≤1	1	0.3	nr
neomycin/colistin/thonzonium/Hc (Coly-mycin S) <sup>42</sup>	reported	reported	nr	nr	nr	nr	reported
neomycin/colistin/thonzonium/Hc (Cortisporin-TC) <sup>43</sup>	reported	reported	nr	nr	nr	nr	reported
neomycin/polymyxin B/Hc (Cortisporin) <sup>44</sup>	reported	reported	nr	nr	nr	nr	reported

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

Ciprofloxacin may also be associated with fungal ear superinfection.<sup>45</sup>

### Patients with Acute Otitis Media and Chronic Suppurative Otitis Media

Drug	Taste Perversion	Ear pain/discomfort	Pruritus	Paresthesia	Rash	Dizziness
ciprofloxacin/dexamethasone (Ciprodex Otic) <sup>46</sup> n=400	0.5	2.3/3	reported	nr	nr	reported
ofloxacin (Floxin Otic) <sup>47</sup> n=656	7	1	1	1	1	1

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

Neomycin-containing products: Neomycin sensitization appears as a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal.<sup>48, 49, 50</sup>

Hydrocortisone: This drug may be associated with the following adverse effects: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.<sup>51, 52, 53</sup>

## **SPECIAL POPULATIONS<sup>54, 55, 56, 57, 58, 59, 60</sup>**

### **Pediatrics**

Otic fluoroquinolones, Coly-mycin S, and Cortisporin TC are approved for use in pediatric patients; however, the age is not specified.

Cetraxal and Cipro HC are indicated for use in children one year of age and older.

Floxin Otic and CiproDex are approved for usage in children as young as six months old.

### **Pregnancy**

All agents in this class are Pregnancy Category C.

## DOSAGES

Drug	Indication	Dose	Duration (days)	Age	Pkg size
ciprofloxacin (Cetraxal) <sup>61</sup>	Acute Otitis Externa	One single use container to affected ear twice daily (approximately 12 hours apart)	7	1 year and older	14 single use containers (0.25 mL)
ciprofloxacin/dexamethasone (Ciprodex Otic) <sup>62</sup>	All indications	4 drops to affected ear twice daily	7	6 months and older	7.5 mL bottle
ciprofloxacin/hydrocortisone (Cipro HC Otic) <sup>63</sup>	Acute Otitis Externa	3 drops to affected ear twice daily	7	1 year and older	10 mL bottle
neomycin/colistin/ thonzonium/HC (Coly-mycin S) <sup>64</sup>	All indications	3 to 4 drops three to four times daily	10	Pediatrics*	5 mL bottle
	All indications	4 to 5 drops three to four times daily	10	Adults	
neomycin/colistin/ thonzonium/HC (Cortisporin-TC) <sup>65</sup>	All indications	3 to 4 drops three to four times daily	10	Pediatrics*	10 mL bottle
	All indications	4 to 5 drops three to four times daily	10	Adults	
neomycin/polymyxin B/HC (Cortisporin) <sup>66</sup>	All indications	3 drops three four times daily	10	2 years and older	10 mL bottle
	All indications	4 drops three four times daily	10	Adults	
ofloxacin (Floxin Otic) <sup>67</sup>	Acute Otitis Externa	5 drops to affected ear daily	7	6 mo-13 yr	5 and 10 mL bottles; 0.25 mL single dose units
	Otitis Externa	10 drops to affected ear daily	7	13 years and older	
	Acute Otitis Media	5 drops to affected ear twice daily	10	1-12 years	
	Chronic Suppurative Otitis Media	10 drops to affected ear twice daily	14	12 years and older	

\* Specific pediatric age not listed in package insert.

## CLINICAL TRIALS

### Search Strategy

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the use of all drugs in this class and the FDA-approved indications. Comparative clinical trials have been performed with some of the agents in this class. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint



assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.

Very little comparative literature of good quality is available. Due to the differences in international bacterial susceptibility, only studies performed in the United States were considered. Most studies were performed in a single-masked manner.

### **ciprofloxacin/dexamethasone (Ciprodex) and ofloxacin (Floxin Otic)**

In a multicenter trial of 599 children (ages six months to 12 years) with acute otitis media with otorrhea through tympanostomy tubes (AOMT), patients were randomized to receive either ciprofloxacin/dexamethasone four drops twice daily for seven days or ofloxacin five drops twice daily for 10 days.<sup>68</sup> In the observer-masked trial, clinical signs and symptoms of AOMT were evaluated at clinic visits on days one, three, 11, and 18 (test of cure). Pathogens included *Streptococcus pneumoniae* (16.8 percent), *S. aureus* (13 percent), *P. aeruginosa* (12.7 percent), *Haemophilus influenzae* (12.4 percent), *Staphylococcus epidermidis* (10.2 percent), and *Moraxella catarrhalis* (4.1 percent). Clinical cure rates at the test-of-cure visit were better in the ciprofloxacin/dexamethasone group (90 versus 78 percent;  $p=0.0025$ ). Microbiologic success was 92 percent for the ciprofloxacin/dexamethasone group and 81.8 percent for the ofloxacin group ( $p=0.0061$ ). Fewer treatment failures were seen with ciprofloxacin/dexamethasone (4.4 percent) than ofloxacin (14.1 percent). Both treatments had similar adverse event profiles.

### **ciprofloxacin/dexamethasone (Ciprodex) and neomycin/polymyxin B/hydrocortisone**

A randomized, observed-masked trial enrolled 468 patients over one year of age with acute otitis externa and intact tympanic membranes to compare the efficacy and safety of seven-day treatment with ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone.<sup>69</sup> Patients were randomized to ciprofloxacin 0.3%/dexamethasone 0.1% suspension given as three to four drops twice daily or neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1% otic suspension given as three to four drops three times daily. Patients with positive cultures ( $n=396$ ) had a clinical cure rate at day 18 of 90.9 percent with the ciprofloxacin/dexamethasone product versus 83.9 percent with the neomycin combination product ( $p=0.0375$ ). Microbiological cure rates were also significantly higher in the ciprofloxacin/dexamethasone group (94.7 versus 86 percent;  $p=0.0057$ ). Both treatments were well tolerated.

### **ciprofloxacin (Cetraxal) and neomycin/polymyxin B/hydrocortisone**

To compare efficacy and safety, a multicenter, observer-blinded study of 630 patients with acute otitis externa was conducted.<sup>70</sup> Patients were randomized to receive either ciprofloxacin 0.2% twice daily or neomycin/polymyxin B/hydrocortisone otic solution three times daily for seven days. Clinical cure was achieved at the test-of-cure in 86.6 percent for the ciprofloxacin-treated group versus 81.1 percent for the neomycin/polymyxin B/hydrocortisone group. Ciprofloxacin was shown to be noninferior to neomycin/polymyxin B/hydrocortisone. The clinical cure rate for patients with baseline cultures showing *P. aeruginosa* was 87.5 percent in the ciprofloxacin group and 78.6 percent in the

neomycin/polymyxin B/hydrocortisone group. In patients with baseline cultures showing *S. aureus*, the clinical cure rate was 72.7 percent for the ciprofloxacin group and 75.9 percent for the neomycin/polymyxin B/hydrocortisone group.

### **ciprofloxacin/hydrocortisone (Cipro HC) and neomycin/polymyxin B/hydrocortisone (Cortisporin) plus systemic amoxicillin**

A randomized, multicenter, active-control, observer-blind, non-inferiority trial of 206 adult and children patients with acute otitis externa compared ciprofloxacin/hydrocortisone with neomycin/polymyxin B/hydrocortisone plus systemic amoxicillin for clinical equivalence.<sup>71</sup> Patients received either ciprofloxacin/hydrocortisone otic three drops twice daily for seven days or neomycin/polymyxin B/hydrocortisone two drops (child) or four drops (adult) plus systemic amoxicillin 250 mg three times daily for 10 days. Safety was evaluated in all patients; efficacy was evaluated in 151 patients. The primary efficacy variable was response to therapy seven days after treatment ended (test of cure). The study demonstrated clinical non-inferiority of ciprofloxacin/hydrocortisone group when compared to neomycin/polymyxin B/hydrocortisone plus amoxicillin. Response to therapy for ciprofloxacin/hydrocortisone was 95.71 percent versus 89.83 percent for neomycin/polymyxin B/hydrocortisone plus amoxicillin. Both groups had a median time to end of pain of six days.

### **ofloxacin (Floxin Otic) and neomycin/polymyxin B/hydrocortisone (Cortisporin)**

Adults and children with otitis externa were randomized to receive ofloxacin otic solution 10 drops or five drops twice daily, respectively, or neomycin/polymyxin B/hydrocortisone otic solution four drops or three drops four times daily for ten days.<sup>72</sup> A total of 314 adults and 287 children were enrolled. In the investigator-blinded study, the overall clinical response was a cure rate of 97 percent of ofloxacin-treated children and 95 percent of neomycin combination-treated children (p=NS). The overall clinical response was cure in 82 percent of ofloxacin-treated adults and 84 percent of neomycin combination-treated adults (p=NS). There were no differences in the incidence of any adverse events between treatment arms.

A double-blind study enrolled 52 patients with active chronic suppurative otitis media (CSOM). Patients were randomized to receive treatment for two weeks with either topical ofloxacin or neomycin/polymyxin B/hydrocortisone.<sup>73</sup> At the conclusion of the study, microbiologic eradication was noted in 81 percent and 75 percent of patients, respectively (p=NS). Clinical cure rates were 89 percent for ofloxacin and 79 percent for neomycin/polymyxin B/hydrocortisone (p=NS). In the study, ofloxacin had better coverage against *S. aureus* (93 percent versus 68 percent), *S. epidermidis* (83 percent versus 73 percent) and *P. aeruginosa* (100 percent versus 86 percent). The adverse events were similar in each group.

## SUMMARY

Otic antibiotics provide an alternative to other topical antibiotics in the treatment of acute otitis media in children with tympanostomy tubes and are effective treatments for acute otitis externa.

Since many AOMT patients have received multiple antibiotics prior to getting tympanostomy tube placement, higher rates of antibiotic resistance may be noted in these patients. Due to the high levels of antibiotic achieved, the use of broad spectrum fluoroquinolones may overcome some of the bacterial resistance. While the addition of a corticosteroid may be of benefit in reducing inflammation, some consider the use of corticosteroids unnecessary.

The safety and efficacy of topical fluoroquinolones for the treatment of ear infections in children and adults is well documented.

## REFERENCES

- 1 Cetraxal [package insert Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 2 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 3 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 4 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 5 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; April 2003.
- 6 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; July 2009.
- 7 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 8 Ruohola A, Meurman O, Nikkari S. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis. 2006; 43(11):1417-22.
- 9 Rosenfeld RM, Brown L, Cannon CR, et al for the American Academy of Otolaryngology--Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2006; 134(4 Suppl):S4-23. Available at: [http://oto.sagepub.com/content/150/1\\_suppl/S1.full](http://oto.sagepub.com/content/150/1_suppl/S1.full). Accessed July 31, 2014.
- 10 Sander R. Otitis externa: a practice guide to treatment and prevention. Am Fam Physician. 2001; 63:927-936,941-942.
- 11 Rosenfeld RM, Singer M, Wasserman JM, et al. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg. 2006; 134(suppl):S24-48.
- 12 Rosenfeld RM, Brown L, Cannon CR, et al for the American Academy of Otolaryngology--Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2006; 134(4 Suppl):S4-23. Available at: [http://oto.sagepub.com/content/150/1\\_suppl/S1.full](http://oto.sagepub.com/content/150/1_suppl/S1.full). Accessed July 31, 2014.
- 13 Lieberthal AS, Ganiats TG, Cox EO, et al for the American Academy of Pediatrics and the American Academy of Family Physicians. Clinical Practice Guidelines: Diagnosis and Management of Acute Otitis Media. Pediatrics. 2004; 113(5):1451-1465. Available at: <http://pediatrics.aappublications.org/content/131/3/e964.full>. Accessed July 31, 2013.
- 14 Lieberthal AS, Carroll AE, Chonmaitree T, et al for the American Academy of Pediatrics. Clinical Practice Guidelines: Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013; 131(3):964-999. Available at: <http://pediatrics.aappublications.org/content/131/3/e964.full>. Accessed July 31, 2013.
- 15 Parry D, et al. Middle Ear, Chronic Suppurative Otitis, Medical Treatment. <http://emedicine.medscape.com/article/859501-overview>. Updated October 13, 2011. Accessed July 29, 2014.
- 16 Dohar J. Eardrops for Otorrhoea. In: Alper CM, Bluestone C, Dohar JE, Mandel EM, Casselbrant ML eds. Advanced Therapy of Otitis Media. Hamilton: BC Decker Publications, 2004;pp. 246-53.
- 17 Weber PC, et al. The development of antibiotic resistant organisms with the use of ototopical medications. Otolaryngol Head Neck Surg. 2004; 130(3 Suppl):S89-94.
- 18 Wai TK, Tong MC. A benefit-risk assessment of ofloxacin otic solution in ear infection. Drug Saf. 2003; 26(6):405-20.
- 19 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 20 Cetraxal [package insert Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 21 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 22 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 23 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 24 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 25 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 26 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 27 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 28 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; July 2009.
- 29 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 30 Cetraxal [package insert]. Columbia, SC; Ritedose Corporation; April 2009.
- 31 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 32 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 33 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 34 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.

- 35 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; July 2009.
- 36 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 37 Cetraxal [package insert]. Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 38 Cetraxal [package insert]. Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 39 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 40 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 41 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 42 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 43 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 44 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 45 Cetraxal [package insert]. Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 46 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 47 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 48 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 49 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 50 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 51 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 52 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 53 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 54 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 55 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 56 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 57 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 58 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 59 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; July 2009.
- 60 Cetraxal [package insert]. Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 61 Cetraxal [package insert]. Ridgeland, MS; Wraser Pharmaceuticals; April 2009.
- 62 Ciprodex Otic [package insert]. Fort Worth, TX; Alcon Laboratories; November 2012.
- 63 Cipro HC Otic [package insert]. Fort Worth, TX; Alcon Laboratories; 2006.
- 64 Coly-mycin S [package insert]. Rochester, MI; JHP Pharmaceuticals; June 2009.
- 65 Cortisporin TC [package insert]. Rochester, MI; JHP Pharmaceuticals; July 2009.
- 66 Cortisporin Otic [package insert]. Bristol, TN; Monarch Pharmaceuticals; May 2010.
- 67 Floxin Otic [package insert]. Montvale NJ; Daiichi Pharmaceutical; November 2006.
- 68 Roland PS, Kreisler LS, Reese B, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes. *Pediatrics*. 2004; 113(1 Pt 1):e40-6.
- 69 Roland PS, Pien FD, Schultz CC, et al for the Ciprodex Otic AOE Study Group. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. *Curr Med Res Opin*. 2004; 20(8):1175-83.
- 70 Drehobl M, Guerrero JL, Lacarte PR, et al. Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa. *Curr Med Res Opin*. 2008; 24(12):3531-42.
- 71 Roland PS, Belcher BP, Bettis R, et al. A single topical agent is clinically equivalent to the combination of topical and oral antibiotics treatment for otitis externa. *Am J Otolaryngol*. 2008; 29(4):255-61.
- 72 Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. *Arch Otolaryngol Head and Neck Surg*. 1997; 123:1193-1200.
- 73 Tong MC, Woo JK, van Hasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. *J Laryngol Otol*. 1996; 110(4):309-14.